4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Purity ≥99,5% (GC) Pabrik Hot Sale
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Jeneng Kimia | 4,6-Dichloro-2-Methylpyrimidine |
sinonim | 2-Metil-4,6-Dichloropyrimidine;2,4-Dichloro-6-Methylpyrimidine |
Nomer CAS | 1780-26-3 |
Nomer CAT | RF-PI687 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C5H4Cl2N2 |
Bobot Molekul | 163.00 |
Titik Lebur | 41,5 ~ 45,5 ℃ (lit.) |
Kelarutan (Soluble in) | Metanol |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Kristal Putih utawa Off-White |
Kemurnian / Metode Analisis | ≥99,5% (GC) |
Mundhut ing Pangatusan | ≤0,50% |
Sisa ing Ignition | ≤0,20% |
Impurity Tunggal | ≤0,50% |
Total Impurities | ≤0,50% |
Standar Tes | Standar Perusahaan |
Panggunaan | Pharmaceutical Intermediate;Dasatinib/Moxonidine Intermediate |
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Rute Proses
Paket: Botol, tas Aluminium foil, 25kg / Drum Karton, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) digunakake ing sintesis intermediet farmasi lan API.Produk Preparation: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib Monohydrate (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine minangka jinis obat antihipertensi anyar, sing umum digunakake ing perawatan hipertensi penting.Dibandhingake karo antihipertensi tumindak tengah sing lawas, Moxonidine duwe ikatan sing luwih gedhe karo reseptor imidazoline I1 tinimbang karo reseptor α2.Dasatinib minangka inhibitor kinase onkogenik sing kuat lisan, sing bisa ngalangi sinyal akselerasi replikasi sel kanker, ing Mei 2009, US Food and Drug Administration (FDA) resmi nyetujoni penjualan dasatinib, wis digunakake sacara klinis kanggo perawatan macem-macem kronis. leukemia myeloid (CML), kalebu perawatan leukemia myeloid kronis sing tahan utawa ora toleran karo program perawatan kalebu imatinib mesylate., Leukemia limfoblastik akut kromosom-positif Philadelphia (Ph + ALL) lan perawatan pasien kanthi tumor padhet.